One Fraction Size Does Not Fit All: Patient Preferences for Hypofractionated Radiation Therapy From a Discrete Choice Experiment.
暂无分享,去创建一个
[1] D. Street,et al. Respondent Understanding in Discrete Choice Experiments: A Scoping Review , 2020, The Patient - Patient-Centered Outcomes Research.
[2] S. Beriwal,et al. Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care? , 2020, International Journal of Radiation Oncology*Biology*Physics.
[3] I. El Naqa,et al. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development , 2020, International Journal of Radiation Oncology*Biology*Physics.
[4] C. Parker,et al. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] K. Hoffman,et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline , 2019, The Journal of urology.
[6] Alan R. Ellis,et al. Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics.
[7] I. Kaplan,et al. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.
[8] J. Mahlich,et al. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan , 2018, American journal of men's health.
[9] Peter Vickerman,et al. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity , 2018, The European Journal of Health Economics.
[10] S. Thompson,et al. The enablers, barriers and preferences of accessing radiation therapy facilities in the rural developed world – a systematic review , 2017, BMC Cancer.
[11] M. Hudson,et al. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments , 2017, BMJ Open.
[12] L. Eliasson,et al. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment. , 2017, Clinical therapeutics.
[13] Alison C. Tree,et al. The Role of Hypofractionated Radiotherapy in Prostate Cancer , 2017, Current Oncology Reports.
[14] Maarten J. IJzerman,et al. Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] Bas Donkers,et al. Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide , 2015, The Patient - Patient-Centered Outcomes Research.
[16] L. Longworth,et al. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[17] Caroline Vass,et al. Risk as an Attribute in Discrete Choice Experiments: A Systematic Review of the Literature , 2014, The Patient - Patient-Centered Outcomes Research.
[18] E. Steyerberg,et al. Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment , 2013, British Journal of Cancer.
[19] Sarah Ronaldson,et al. Ordinal preference elicitation methods in health economics and health services research: using discrete choice experiments and ranking methods. , 2012, British medical bulletin.
[20] Joanna Coast,et al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. , 2012, Health economics.
[21] Mandy Ryan,et al. Discrete choice experiments in health economics: a review of the literature. , 2012, Health economics.
[22] M. Stockler,et al. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer , 2012, British Journal of Cancer.
[23] Masatoshi Kudo,et al. Identifying and prioritizing strategies for comprehensive liver cancer control in Asia , 2011, BMC health services research.
[24] Andrew Lloyd,et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] G. Elwyn,et al. Implementation Science BioMed Central Debate , 2009 .
[26] John M. Rose,et al. Asymmetric preference formation in willingness to pay estimates in discrete choice models , 2008 .
[27] Ola Svenson,et al. Patient‐focussed decision‐making in early‐stage prostate cancer: insights from a cognitively based decision aid , 2004, Health expectations : an international journal of public participation in health care and health policy.
[28] J. Concato,et al. Treatment Decisions for Localized Prostate Cancer Asking Men What ’ s Important , 2000 .
[29] Deborah Marshall,et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.